- Home
- RPRX vs ES Comparison
RPRX vs ES Comparison
Compare RPRX & ES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RPRX | ES |
|---|---|---|
| Founded | 1996 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9B | 26.9B |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | RPRX | ES |
|---|---|---|
| Price | $57.41 | $64.24 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 16 |
| Target Price | $65.13 | ★ $73.58 |
| AVG Volume (30 Days) | ★ 2.7M | 2.0M |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | 1.61% | ★ 4.91% |
| EPS Growth | N/A | ★ 100.88 |
| EPS | 0.71 | ★ 1.75 |
| Revenue | $2,378,193,000.00 | ★ $13,547,244,000.00 |
| Revenue This Year | $47.32 | $1.60 |
| Revenue Next Year | $8.70 | $5.04 |
| P/E Ratio | $82.08 | ★ $36.74 |
| Revenue Growth | 5.06 | ★ 13.83 |
| 52 Week Low | $35.23 | $62.72 |
| 52 Week High | $64.38 | $76.57 |
Technical Indicators
Market Signals| Indicator | RPRX | ES |
|---|---|---|
| Relative Strength Index (RSI) | 41.62 | 27.71 |
| Support Level | $57.75 | N/A |
| Resistance Level | $58.84 | $71.44 |
| Average True Range (ATR) | 1.07 | 1.09 |
| MACD | -0.12 | -0.30 |
| Stochastic Oscillator | 24.51 | 9.48 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About ES Eversource Energy (D/B/A)
Eversource Energy is a diversified holding company with subsidiaries that provide rate-regulated electric, gas, and water distribution service to more than 4 million customers in the Northeast US. Eversource expanded its service territories with acquisitions of NStar (2012), Aquarion (2017), and Columbia Gas (2020). In 2024 Eversource exited its 50% partnership with European utility Orsted to develop 2 gigawatts of offshore wind projects in the Northeast US. It plans to sell Aquarion in 2026. The company exited most of its unregulated businesses in 2006.